CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Peripheral T Cell Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States
Contact: Principal Investigator (Anne Beaven, MD)Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
Contact: Study coordinator (Jana Hall Project Manager) · UNCImmunotherapy@med.unc.edu · 919-966-4432Contact: Principal Investigator (Rakhee Vaidya, MD)
Study leads
Anne Beaven, MD
Principal Investigator
UNC Chapel Hill